Ergomed acquires ADAMAS at 14.2x EBITDA

Guildford-based pharmaceutical firm Ergomed has announced the acquisition of ADAMAS Consulting Group for £25.6 million. The price represents approximately a 14.2x multiple of ADAMAS’ £1.8 million adjusted EBITDA for 2021, generated on revenue of £8.5 million.

Ergomed has said that it expects the acquisition, which reflects an enterprise value of £24.2 million along with £1.4 million in acquired cash, to be immediately earnings enhancing and to generate ongoing synergies and strategic benefits over coming years. A key asset that Ergomed will be acquiring is ADAMAS’ global reach, which will significantly enhance Ergomed’s presence.

Based in Berkshire, ADAMAS provides regulatory compliance and consulting for clients in the global pharmaceutical sector. The company provides a range of quality assurance services and specialises in auditing for pharma manufacturing, clinical trials and pharmacovigilance systems.

It has over 100 active clients and has worked with more than 700 companies in the pharmaceutical industry, including 40 of the 50 largest firms in the global biotech and pharma sectors. Post-acquisition, ADAMAS will continue to operate as an independent consultancy, with its senior executive team remaining in place.

The takeover is in line with Ergomed’s M&A strategy, through which it targets deals that enhance its global presence, broaden its service offering and ensure that quality and compliance remain at the heart of its growth.

The acquisition also reflects a wider boom in professional services M&A, with professional services firms in the pharmaceutical and healthcare sectors having become highly sought-after acquisition targets in recent years, particularly since the start of the COVID-19 pandemic.

Ergomed Executive Chairman Dr Miroslav Reljanović said: “This value-enhancing acquisition aligns with our disciplined M&A strategy, strengthening our position as a focused premium pharmaceutical services business, whilst further building our Group’s scale in the strategically important US, Europe and APAC regions.”

“With this deal we are addressing the pharmaceutical industry’s ever-growing need for best practice quality assurance due to the increasing complexity of drug development, pharmacovigilance and manufacturing processes and associated regulatory requirements.”

“We look forward to working with Ian and the ADAMAS management team as we invest in and support this business to deliver a broader service offering to clients.”


Find businesses for sale here.

If you are looking for an exit, We can help!

Share this article

Latest Businesses for Sale

---

---

---

View more businesses for sale